
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ
@kidneycancerj
An International, Scientific, Peer-reviewed Journal (ISSN 1933-0863) for latest advances & quality research in Kidney Cancers published by BioMedzGlobal.com
ID: 1191556936778633223
https://www.kidney-cancer-journal.com/ 05-11-2019 03:25:02
913 Tweet
1,1K Followers
4,4K Following

Update on #COSMIC313 trial presented by the one and only Laurence Albiges: C+N+I showed sustained PFS & ORR benefits over P+N+I in 1L intermediate/poor risk pts. OS was similar between arms (HR 1.02). Addition of Cabo to N+I overcomes M2-like macrophage-mediated immune suppression


Updated clinical outcomes from the phase I study on cabozantinib (cabo) + nivolumab (nivo) with or without CBM588 in metastatic RCC patients! 📊🔬 New insights into combination therapy for better outcomes ASCO #GU25 Hedyeh Ebrahimi Sumanta K. Pal, MD, FASCO


Eye-opening talk by Turajlic Lab @ The Crick on the future of biomarkers in #RCC, especially genomic, highlighting important challenges ASCO #GU25 The Crick OncLive.com Yüksel Ürün Emre Yekedüz


New kid on the block! Toni Choueiri, MD HIF-2α Inhibitor Cas in ccRCC: Early Promise! -Active across IMDC risk groups in pretreated ccRCC. -Grade 3 anemia (36%) & hypoxia (6-9%), no Grade ≥4 TEAEs. -Next: PEAK-1 (Cas + Cabo) & first-line IO combo trials! #GU25 @asco @oncoalert



Racial Disparities in RCC: Insights from France! Xiaofan Lu, PhD, UroCCR No race-based survival difference—unlike U.S. data, healthcare access may play a role. #GU25 @asco @oncoalert #cancer #oncology Toni Choueiri, MD Petros Grivas 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 OncLive.com Andrea Apolo, M.D. joaquim bellmunt


Excellent updated data from Cosmic 313. Positive PFS but no difference in OS. Many lessons learned. Transcriptomic work demonstrated tumors with high M2 macrophages derived benefit. Laurence Albiges Toni Choueiri, MD #GU25


Updated data from Calypso trial demonstrating activity of savolitinib + durvalumab in MET driven papillary RCC. #GU25 Toni Choueiri, MD Tom Powles


SAMETA: the 1st biomarker driven R3 papillary RCC study #GU25 . CALYPSO is the phase 2 data supporting it. RR PFS and OS in the MET driven group looks promising for durva/savolitinib. drfrankiejs also presents baseline and dynamic ctDNA analysis. A new biomarker in PRCC?


🔥 Excellent talk by Matt Campbell MD, MS diving into the mechanisms of immunotherapy resistance in RCC! 💡🔬 #RCC #GU25 #Immunotherapy


Great last session ASCO #GU25 - interactive case based discussions for hard to treat #kidneycancer. Good to see Raquibul Hannan representing UTSW Radiation Oncology UTSW Simmons Cancer Center on expert panel, along w friends Maite Bourlon Matt Campbell MD, MS Viraj Master!



🆕Excited that our FKSI-23 measure, designed to assess HRQOL in patients with localized and advanced RCC, is available on the FACIT website: facit.org/measures/fksi-… Tom Powles Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Sarah P. Psutka MD MS Brian Rini, MD Elizabeth Plimack MD Viraj Master Viktor Grünwald Laurence Albiges




Brilliant work from Cristiane D Bergerot (mentored by Tom Powles) to introduce a novel #HRQOL metric for #kidneycancer. This one is different, folks! There are separate, short components of this that can be used for #localized & #metastatic dz (see “Scoring Document”). Developed with a


🚨#IKCS24 Proceedings is out! kidney-cancer-journal.com/IKCSNA-Proc.php 📕flipbook: kidney-cancer-journal.com/IKCS24-Proc2.p… 👉25 years of #ICKS24 - Special editorials by Brian Rini, MD Thomas Hutson, DO, PharmD, PhD FACP Salvatore La Rosa Kidney Cancer


So pleased to share research highlights from our #IKCSNA24 mtg marking ✨25 yrs✨ of the KCA's work to gather the scientific community! Find in-depth articles, editorials, and personal perspectives from leading #kidneycancer experts at Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ: kidney-cancer-journal.com/IKCSNA-Proc.php


